Is response guided therapy dead? Low cure rates in patients with detectable hepatitis C virus at week 4 of treatment

Hepatology International

Volumn 10, Issue 4, 2016, Pages 624-631

  Thornton, Karla ^a   Deming, Paulina ^b   Manch, Richard A ^c   Moore, Ann ^c   Kohli, Anita ^c   Gish, Robert ^c   Sussman, Norman L ^d   Khaderi, Saira ^d   Scott, John ^e   Mera, Jorge ^f   Box, Terry ^g   Qualls, Clifford ^h   Sedillo, Miranda ^h   Arora, Sanjeev ^a  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f Cherokee Nation Health Service   (United States)

^g UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

HCV; Hepatitis C; Project ECHO; Response guided therapy; Sofosbuvir

Indexed keywords

ASPARTATE AMINOTRANSFERASE; INTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; VIRUS RNA; ANTIVIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE PLATELET RATIO INDEX; CHRONIC HEPATITIS C; COMBINATION DRUG THERAPY; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 6; HUMAN; HUMAN CELL; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONHUMAN; PRIORITY JOURNAL; RESPONSE GUIDED THERAPY; RETROSPECTIVE STUDY; SEX DIFFERENCE; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; VIRUS DETECTION; AGED; DRUG EFFECTS; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; RISK FACTOR; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

AGED; ANTIVIRAL AGENTS; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; RNA, VIRAL; SOFOSBUVIR; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84964334037     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-016-9725-6     Document Type: Article

References (25)

1. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308(24):2584–2593
2. Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993;328(7):465–470
3. Younossi ZM, Stepanova M, Gerber L, Nader F, Frost S, Hunt SL. P717 Improvement of central fatigue is associated with sustained virologic response (SVR) following sofosbuvir (SOF) containing regimens. J Hepatol 2014;60(1):S308
4. Arase Y, Suzuki F, Suzuki Y, et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 2009;49(3):739–744
5. Takahashi K, Nishida N, Kawabata H, Haga H, Chiba T. Regression of Hodgkin lymphoma in response to antiviral therapy for hepatitis C virus infection. Intern Med 2012;51(19):2745–2747
6. Lawitz EJ, Membreano FE. Response-guided therapy in patients with genotype 1 hepatitis C virus: Current status and future prospects. J Gastroenterol Hepatol 2014;29(8):1574–1581
7. Fried MW, Hadziyannis SJ, Shiffman ML, et al. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol 2011;55:69–75
8. Lawitz, E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878–1887
9. Arora S, Thornton K, Komaromy M, et al. Demonopolizing medical knowledge. Academic Medicine 2014;89(1):30–32
10. Arora S, Kalishman S, Thornton K, et al. Expanding access to hepatitis C virus treatment—Extension for Community Healthcare Outcomes (ECHO) project: Disruptive innovation in specialty care. Hepatology 2010;52(3):1123–1133
11. Arora S, Thornton K, Murata G, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med 2011;364:2199–2207
12. Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011;53:726–36
13. Taylor N, Haschke-Becher E, Greil R, et al. Performance characteristics of the COBAS Ampliprep/COBAS TaqMan v2.0 and the Abbott RealTime hepatitis C assays—implications for response-guided therapy in genotype 1 infections. Antiviral Ther 2014;19(5):449–454
14. Sidharthan S, Kohli A, Sims Z, et al. Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy. Clin Infect Dis 2015;60(12):1743–1751
15. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. New Engl J Med 2013;368(20):1867–1877
16. Dieterich D, Bacon B, Flamm SL et al. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population. [Abstract 46.] 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). 2014a;220A; Boston, MA
17. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. New Engl J Med 2014;370:1483–1493
18. Kohli A, Osinusi A, Sims Z, et al. Virologic response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Lancet 2015;385:1107–1113
19. American Association for the Study of Liver Diseases. Recommendations for testing, managing, and treating Hepatitis C. [Internet]. Arlington (VA): doi:10.1002/hep.27950. Available from: http://www.hcvguidelines.org/. Jointly published with Infectious Diseases Society of America
20. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. New Engl J Med 2014;370:1483–1493
21. Bourliere M, Sulkowski M, Omata M, et al. An integrated safety and efficacy analysis of > 500 patients with compensated cirrhosis treated with ledipasvir/sofosbuvir with or without ribavirin. 65th Annual Meeting of the American Association for the Study of Liver Diseases; 2014; Boston, MA
22. Poordad F, Hezode C, Trinh R, et al. ABT-450/r–ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. New Engl J Med 2014;370:1973–1982
23. Simeprevir [package insert]. Titusville NJ: Janssen Therapeutics, 2013
24. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014;384:1756–1765
25. Lawitz E, Flamm S, Yang JC, et al. Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks. 50th Annual Meeting of the European Association for the Study of the Liver; 2015; Vienna